AVIGENICS LIMITED

Company Registration Number:
13211134 (England and Wales)

Unaudited statutory accounts for the year ended 28 February 2023

Period of accounts

Start date: 01 March 2022

End date: 28 February 2023

AVIGENICS LIMITED

Contents of the Financial Statements

for the Period Ended 28 February 2023

Company Information - 3
Report of the Directors - 4
Balance sheet - 5
Additional notes - 7
Balance sheet notes - 10

AVIGENICS LIMITED

Company Information

for the Period Ended 28 February 2023




Director: Venkatraghavan Madabushi
Secretary: Venkatraghavan Madabushi
Registered office: 134
Imperial Drive
North Harrow
GBR
HA2 7HT
Company Registration Number: 13211134 (England and Wales)

AVIGENICS LIMITED

Directors' Report Period Ended 28 February 2023

The directors present their report with the financial statements of the company for the period ended 28 February 2023

Principal Activities

Bird DNA Technical testing and analysis

Directors

The director(s) shown below were appointed to the company during the period
Venkatraghavan Madabushi
01 March 2022

Secretary
Venkatraghavan Madabushi

This report was approved by the board of directors on 30 August 2023
And Signed On Behalf Of The Board By:

Name: Venkatraghavan Madabushi
Status: Director

AVIGENICS LIMITED

Balance sheet

As at 28 February 2023


Notes

2023
£

2022
£
Fixed assets
Total fixed assets: - -
Current assets
Cash at bank and in hand: 3,633 4,113
Total current assets: 3,633 4,113
Creditors: amounts falling due within one year: 4 ( 940 ) ( 4,008 )
Net current assets (liabilities): 2,693 105
Total assets less current liabilities: 2,693 105
Total net assets (liabilities): 2,693 105

The notes form part of these financial statements

AVIGENICS LIMITED

Balance sheet continued

As at 28 February 2023


Notes

2023
£

2022
£
Capital and reserves
Called up share capital: 1 1
Profit and loss account: 2,692 104
Shareholders funds: 2,693 105

For the year ending 28 February 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

This report was approved by the board of directors on 30 August 2023
And Signed On Behalf Of The Board By:

Name: Venkatraghavan Madabushi
Status: Director

The notes form part of these financial statements

AVIGENICS LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

AVIGENICS LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 2. Employees


    2023

    2022
    Average number of employees during the period 0 0

AVIGENICS LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

  • 3. Off balance sheet disclosure

    No

AVIGENICS LIMITED

Notes to the Financial Statements

for the Period Ended 28 February 2023

4.Creditors: amounts falling due within one year note


2023
£

2022
£
Bank loans and overdrafts 826 408
Other creditors 114 3,600
Total 940 4,008

Credit card and personal cash taken for office expenses